SARS2 and neoplasm: Pharmacological inhibition of FGFRs by means of the selective inhibitor of FGFR1, FGFR2, and FGFR3, BGJ398, was able to hamper SyS growth in vivo in a model of human SyS cell-derived xenografts (SYO-1 cells) and in the conditional SyS mouse model hSS2/Myf5–Cre, where a marked decrease in average tumor number and volume was observed [47].